Leptin enhances the glucose utilization in most insulin target tissues and paradoxically decreases it in white adipose tissue (WAT), but knowledge of the mechanisms underlying the inhibitory effect of central leptin on the insulin-dependent glucose uptake in WAT is limited. After 7 d intracerebroventricular leptin treatment (0.2 g/d) of rats, the overall insulin sensitivity and the responsiveness of WAT after acute in vivo insulin administration were analyzed. We also performed unilateral WAT denervation to clarify the role of the autonomic nervous system in leptin effects on the insulin-stimulated [ 3 H]-2-deoxyglucose transport in WAT. Central leptin improved the overall insulin sensitivity but decreased the in vivo insulin action in WAT, including insulin receptor autophosphorylation, insulin receptor substrate-1 tyrosine-phosphorylation, and Akt activation. In this tissue, insulin receptor substrate-1 and glucose transporter 4 mRNA and protein levels were down-regulated after central leptin treatment. Additionally, a remarkable up-regulation of resistin, together with an augmented expression of suppressor of cytokine signaling 3 in WAT, was also observed in leptin-treated rats. As a result, the insulin-stimulated glucose transporter 4 insertion at the plasma membrane and the glucose uptake in WAT were impaired in leptin-treated rats. Finally, denervation of WAT abolished the inhibitory effect of central leptin on glucose transport and decreased suppressor of cytokine signaling 3 and resistin levels in this tissue, suggesting that resistin, in an autocrine/paracrine manner, might be a mediator of central leptin antagonism of insulin action in WAT. We conclude that central leptin, inhibiting the insulin-stimulated glucose uptake in WAT, may regulate glucose availability for triacylglyceride formation and accumulation in this tissue, thereby contributing to the control of adiposity. (Endocrinology 152: 1366 -1377, 2011) 
Leptin enhances the glucose utilization in most insulin target tissues and paradoxically decreases it in white adipose tissue (WAT), but knowledge of the mechanisms underlying the inhibitory effect of central leptin on the insulin-dependent glucose uptake in WAT is limited. After 7 d intracerebroventricular leptin treatment (0.2 g/d) of rats, the overall insulin sensitivity and the responsiveness of WAT after acute in vivo insulin administration were analyzed. We also performed unilateral WAT denervation to clarify the role of the autonomic nervous system in leptin effects on the insulin-stimulated [ 3 H]-2-deoxyglucose transport in WAT. Central leptin improved the overall insulin sensitivity but decreased the in vivo insulin action in WAT, including insulin receptor autophosphorylation, insulin receptor substrate-1 tyrosine-phosphorylation, and Akt activation. In this tissue, insulin receptor substrate-1 and glucose transporter 4 mRNA and protein levels were down-regulated after central leptin treatment. Additionally, a remarkable up-regulation of resistin, together with an augmented expression of suppressor of cytokine signaling 3 in WAT, was also observed in leptin-treated rats. As a result, the insulin-stimulated glucose transporter 4 insertion at the plasma membrane and the glucose uptake in WAT were impaired in leptin-treated rats. Finally, denervation of WAT abolished the inhibitory effect of central leptin on glucose transport and decreased suppressor of cytokine signaling 3 and resistin levels in this tissue, suggesting that resistin, in an autocrine/paracrine manner, might be a mediator of central leptin antagonism of insulin action in WAT. We conclude that central leptin, inhibiting the insulin-stimulated glucose uptake in WAT, may regulate glucose availability for triacylglyceride formation and accumulation in this tissue, thereby contributing to the control of adiposity. (Endocrinology 152: 1366 -1377, 2011) L eptin modulates glucose homeostasis, acting through both central and peripheral pathways, as an insulinsensitizing factor at the whole-body level (1, 2) . Nevertheless, studies on glucose uptake by different tissues after in vivo leptin treatment suggest that the hormone exerts tissue-specific effects, stimulating glucose utilization in brown adipose tissue, heart, and skeletal muscle but inhibiting glucose uptake in white adipose tissue (WAT) (3, 4) . However, studies concerning the effects of leptin on insulin signaling in WAT have been not only scarce, but also controversial (5) .
Whereas leptin microinjection into ventromedial hypothalamus decreases the insulin-stimulated glucose uptake in WAT (6) , leptin incubation of isolated adipocytes has been reported to inhibit insulin stimulation of glucose transport (7) , to impair only the lipogenic action of insulin (8, 9) , and not to influence insulin-mediated effects (10, 11) . Additionally, we have reported that in vivo chronic leptin administration impairs insulin-stimulated MAPK activity in isolated adipocytes (12) , whereas the insulinstimulated MAPK phosphorylation in WAT was increased after acute in vivo leptin treatment (13) . Taken together, these data strongly suggest a complex regulatory cross talk between leptin and insulin signaling pathways.
Several studies have suggested that the WAT plays a pivotal role in regulating overall insulin sensitivity, although the mechanisms involved are still poorly understood. Thus, decreasing visceral fat by caloric restriction (14) or surgical removal (15) prevents the development of overall insulin resistance. Adipose-selective glucose transporter 4 (GLUT4) gene disruption causes glucose intolerance and hyperinsulinemia (16) , whereas GLUT4 overexpression in fat tissue enhances whole-body insulin sensitivity and glucose tolerance in diabetic mice (17) . Finally, the overexpression in WAT of suppressor of cytokine signaling 3 (SOCS3), known for its insulin inhibitory effects (18) , causes local but not systemic insulin resistance (19) . In fact, an increased SOCS3 expression in adipocytes had been proposed as a potential mediator of the insulin resistance induced by several hormones and cytokines, including leptin, insulin, TNF-␣, and resistin (12, 20 -22) .
Compelling evidence suggests that leptin exerts its metabolic effects predominantly through different hypothalamic nuclei, where the leptin receptor expression is the highest compared with other tissues (23) . By acting on the brain, leptin affects appetite, neuroendocrine pathways, and autonomic nerves, which transmit the hormone signal to the periphery (24) . On the other hand, direct leptin effects have been reported in peripheral tissues that express the leptin receptor (5). However, the relative importance of peripheral vs. central actions of leptin on metabolic effects of the hormone is not well characterized.
Hence, the overall objective of the present work is to study the molecular mechanisms by which central leptin treatment impaired insulin-stimulated glucose uptake in WAT. To this end, we analyzed the effects of chronic central leptin infusion on early steps of the insulin signaling pathway implicated in glucose uptake in WAT. The role of SOCS3 and resistin as mediators of central leptin action regulating glucose availability for fatty acid esterification in this tissue are discussed. This work extends our previous observations examining the effects of in vitro and/or in vivo leptin administration on insulin signaling in isolated adipocytes (12) .
Materials and Methods
Male 3-month-old Wistar rats were randomly housed in individual cages under conditions of climate-controlled quarters with a 12-h light cycle and fed ad libitum standard laboratory diet and water. The animals were handled according to the laws of the European Union and the guidelines of the National Institutes of Health, and the experimental protocols were approved by the institutional committee of bioethics.
WAT denervation
Unilateral autonomic nervous system denervation of the retroperitoneal fat pad (rWAT) was performed according to Kreier et al. (25) . As we previously reported (26) , local denervation in anesthetized rats, as below, was achieved by surgical removing nerves running along blood vessels from the diaphragm to the superior tip of the left rWAT, with the contralateral intact right pad used as control. Five weeks after the surgery, rats were subjected to an intracerebroventricular leptin administration as described below. In agreement with previous reports (27) and supporting the efficiency of the surgical denervation, the weight of the denervated left rWAT increased by ϳ27%, and the total norepinephrine (NE) content in the denervated fat pad was significantly reduced compared with the contralateral intact right pad (5.5 Ϯ 0.4 vs. 9.7 Ϯ 0.3 ng NE/g tissue, respectively; n ϭ 3; P Ͻ 0.001).
Leptin administration
Intracerebroventricular leptin administration was performed as previously described (28) . Briefly, rats were anesthetized with ip ketamine/diazepam/atropine used at 50 mg/kg, 4 mg/kg, and 0.2 mg/kg, respectively (Parke-Davis, Roche and Braun, Spain), and placed in a stereotaxic frame (David Koppf, Tujunga, CA). An opening in the skull was made with a dental drill at Ϫ1.6 mm lateral to the midline and 0.8 mm posterior to bregma. A cannula connected to an osmotic pump (Alzet, Palo Alto, CA) was implanted in the right lateral cerebral ventricle, with a releasing rate of 1 l/h, and filled with 0.0082 g/l (0.2 g/d) rat leptin (Sigma-Aldrich, St. Louis, MO), or its vehicle (PBS). Five groups of rats randomly distributed were investigated: 1) rats infused with leptin (Lep); 2) rats infused with vehicle and allowed to eat ad libitum (SS); 3) rats infused with vehicle and pair-fed to the amount of food consumed by the leptin-infused animals (PF); 4) unilateral denervated rats infused with leptin, and 5) unilateral denervated pair-fed rats infused with vehicle. After 7 d of treatment rats were killed by decapitation or subjected to an iv insulin (10 I.U/kg body weight) (Lily) or saline injection for 30 min and then killed by decapitation. rWAT and epididymal fat pads (eWAT) were dissected and weighed. An aliquot (per triplicate) from each fat pad was immediately used, independently, for glucose transport experiments as tissue explants. The rest of the tissue was flash frozen in liquid nitrogen and stored at Ϫ70 C until use. NE tissue content was measured using a NE research ELISA kit (Demeditec Diagnostics GmbH, Kiel, Germany), fol-lowing the manufacturer's instructions. Plasma triacylglycerides (TAG), glucose, and TAG content in WAT were determined as previously described (29) . Plasma leptin and insulin levels were assayed using specific rat kits from Spi-Bio (Montigny le Bretonneaux, France). Plasma resistin was assessed using a rat resistin ELISA kit (BioVendor, Brno, Czech Republic), following the manufacturer's instructions.
Glucose tolerance tests
Intraperitoneal glucose tolerance tests were performed in overnight-fasted animals as described (26) . Rats from groups 1-3 were weighed and injected ip with 2 g of glucose/kg body weight. Blood samples were obtained from the tail tip at 0, 15, 30, 60, and 120 min after glucose administration, and glucose levels were determined using an Accutrend Glucose Analyzer (Roche Diagnostics Corp., Indianapolis, IN). Plasma insulin levels were determined as above. Overall changes in glucose and insulin during glucose tolerance test were calculated as the area under the curve (AUC) using the GraphPad Prism version 3.03 for Windows (GraphPad Software). The ratio of glucose AUC to insulin AUC was used as an index of whole body insulin sensitivity (30) .
Glucose uptake in WAT explants
Glucose uptake was determined, independently, in rWAT and/or eWAT. Fat pad explants (approximately 20 mg), excluding visible connective tissue and blood vessels, were placed immediately after dissection in 0.5 ml Krebs-Ringer-HEPES (KRH) (pH 7.4) supplemented with 1.2 mM CaCl 2 and 2% BSA (KRH/ Ca 2ϩ -BSA). To analyze the effect of resistin (26 -49, mouse resistin, Phoenix Pharmaceuticals Inc, Belmont, CA) on glucose uptake, WAT explants from control ad libitum rats were preincubated at 37 C in the absence or presence of resistin (200 ng/ml) for 4 h in 0.5 ml KRH/Ca 2ϩ -BSA supplemented with 5.0 mM pyruvate before insulin stimulation. All explants were incubated in the absence or presence of 80 nM insulin for 10 min at 37 C. 2-Deoxyglucose (0.2 mM) and [ 3 H]-2-deoxyglucose (2 Ci/ml) (Amersham Pharmacia Biotech) were then added to the explants and incubated a further 10 min at 37 C. Explants were incubated with the transport stop solution (50 M Cytochalasin B, 5 mM D-glucose) for 10 min at 37 C and washed twice in ice-cold KRH buffer to remove unbound label. Explants were dissolved in NaOH 1N, SDS 0.1%, at 50 C for 2 h, and radioactivity was determined using a Beckman Scintillation counter. Basal glucose uptake was taken as 2-deoxyglucose uptake in the absence of insulin. Data were expressed as pmol 2-deoxyglucose/mg wet weight. The small amount of extracellular 2-deoxyglucose remaining was corrected from the [ 3 H]-2-deoxyglucose content in samples incubated with the transport stop solution for 10 min at 37 C before the transport reaction.
Real-time RT-PCR
Total RNA was isolated from eWAT and/or rWAT using the Trizol reagent (Invitrogen, Carlsbad, CA). The cDNA was synthesized from 1.5 g of DNase-treated RNA by using the reversetranscriptase activity from Moloney murine leukemia virus (Life Technologies, Inc.-BRL, Carlsbad, CA), and p[dN] 6 (Boehringer Mannheim, Germany) as random primer. Relative quantitation of insulin receptor (IR)-A, IR-B, insulin receptor substrate (IRS)-1, GLUT4, SOCS3, and resistin gene expression was performed by TaqMan real-time PCR according to the manufacturer's protocol on an ABI PRISM 7500 FAST Sequence Detection System instrument and software (PE Applied Biosystem, Foster City, CA). IRS-1, GLUT4, SOCS3, and resistin were measured using Pre-Developed TaqMan Assay Reagents (PE Applied Biosystem). For IR-B, the primers and probe sets were designed using the manufacturer's software and sequences available in GenBank (M29014). The probe was 5Ј-TCTTCAGGCAATG-GTGCT-3Ј and spanned 18 nucleotides from the exon 11. For IR-A the primers used were 5Ј-CCCACCTTTTGAGTCTGAC-GAT-3Ј and 5Ј-GGGATGGCCTGGGAACA-3Ј, flanking a fragment of 182 bp. To determine the accumulation of IR-A PCR product, SYBR Green dye was used as a real-time reporter of the presence of double-stranded cDNA.
To normalize the amount of sample cDNA added to the reaction, amplification of endogenous control 18S rRNA was included in separate wells using VIC (TaqMan Assay) or SYBR Green as real-time reporter. The ⌬⌬C T method was used to calculate the relative differences between experimental conditions and control groups as fold change in gene expression (31) .
Subcellular fractionation and immunoblot analysis
The tissue was homogenized in 2 volumes of isolation medium [250 mM sucrose, 10 mM HEPES (pH 7.4), 1 mM EDTA, 2 mM EGTA, 5 mM NaN 3 , 5 mM NaF, 1 mM phenylmethylsulfonylfluoride, 2 mM Na 3 VO 4 , 10 g/ml leupeptin, 10 g/ml aprotinin, 1 g/ml pepstatin], centrifuged at 450 ϫ g for 5 min, and the infranadant was considered as total extract. The purified plasma membrane (PM), light membranes (LM), and the cytosolic fraction (CYT) were obtained as described previously (32) . Membrane protein concentrations were determined using the bicinchoninic (BCA) protein assay kit from Pierce Biotechnology (Cultek, Spain). As we have previously reported (26) , ␤-actin, Na ϩ /K ϩ -ATPase, and TGN38 were used as controls for protein loading of the total tissue extract, PM, and LM fractions, respectively (data not shown). Samples from all experimental conditions were run on the same gel, immunoblotted, and detected as previously described (33 
Statistical analysis
Statistical analysis was performed using the GraphPad Prism version 3.03 for Windows (GraphPad Software). Significant differences among groups were determined by one-way ANOVA followed by Tukey test.
Results

Central leptin reduces food intake, body weight, and adiposity
As expected, central leptin administration reduced the daily food intake, and this was accompanied by body weight loss in these rats. Moreover, leptin treatment decreased by 26% and 37% the weights of eWAT and rWAT, respectively, and according to its well-known lipostatic function, central leptin infusion significantly reduced TAG levels in plasma and in WAT. Finally, in agreement with our previous observations (29) , fasting plasma insulin levels were also decreased compared with salinetreated pair-fed control rats ( Table 1) .
Effects of central leptin on insulin sensitivity and on glucose uptake in WAT
To investigate the consequences of central leptin treatment on the overall insulin sensitivity we performed an ip glucose tolerance test. As shown in Fig.  1A , the insulin secretion in leptin-treated rats was significantly lower than in saline-infused ad libitum and pair-fed control rats. Consistent with this, the insulin sensitivity index, calculated as the ratio of glucose AUC to insulin AUC, was improved significantly in leptin-treated rats. This result implies that leptin increases the whole-body insulin sensitivity.
Because leptin modulates the glucose utilization in a tissue-specific manner, we analyzed the effects of the hormone on 2-deoxyglucose uptake in WAT explants from saline-treated pair-fed control and leptin-treated rats. , and 120 min after the glucose administration. Overall changes in glucose and insulin during glucose tolerance test were calculated as the AUC. The ratio of glucose AUC to insulin AUC was used as an index of whole body insulin sensitivity. Data are the mean Ϯ SEM of three to four rats per group (**, P Ͻ 0.05). B, Glucose uptake in WAT explants after unilateral autonomic nervous system denervation (rat groups 4 -5, see Materials and Methods). rWAT explants were used for [ 3 H]-2-deoxyglucose uptake measurements in the absence or presence of 80 nM insulin stimulation for 10 min. Results are the mean Ϯ SEM of three to four rats per group, made in triplicate (**, P Ͻ 0.005; ***, P Ͻ 0.001). SS, vehicle-infused ad libitum-fed rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats; Lep- 
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Central leptin treatment had no effect on the basal but significantly decreased the insulin-stimulated glucose uptake in rWAT explants compared with saline-treated pairfed control rats (Fig. 1B) . Similar results were observed in eWAT (not shown). To investigate whether central leptin effects on WAT were mediated by neural circuits, we performed surgical denervation of the left rWAT, leaving the contralateral intact right fat pad as an internal control. As shown in Fig. 1B , local autonomic denervation abolished the inhibitory effect of central leptin on glucose transport and restored the insulin stimulation of glucose uptake in rWAT. Because the effect of central leptin took place in the face of unaltered circulating plasma leptin levels (Table 1) , this result suggests that leptin action in WAT is indeed indirect and mediated by the autonomic nervous system. We also examined the ability of insulin to induce the translocation of GLUT4 from intracellular compartments (LM) to the PM in eWAT upon in vivo insulin stimulation. In adipose tissue from saline-infused ad libitum and pairfed control rats, in vivo insulin administration stimulated the GLUT4 translocation from LM to PM (Fig. 2) . However, the ability of insulin to increase the amount of GLUT4 insertion at the PM was prevented by leptin even though the GLUT4 redistribution from LM was unaffected (Fig. 2, A and B) .
Central leptin inhibits early steps of in vivo insulin signaling in WAT
To analyze the mechanism underlying the inhibitory effect of central leptin on glucose uptake and GLUT4 translocation upon acute in vivo insulin stimulation, we studied the effects of a 7-d central leptin infusion on early steps of insulin signaling pathway known to regulate these processes in WAT, such as IR and IRS-1. At the basal state we did not observe changes in IR and IRS-1 tyrosine-phosphorylation after chronic leptin treatment (Fig.  3, A and B) . However, leptin treatment significantly augmented the basal content of IRS-1 phosphorylation on Ser307 (Fig. 3C) .
The intravenous acute insulin administration stimulated both the IR autophosphorylation and the IRS-1 tyrosine phosphorylation in ad libitum and pair-fed control rats (Fig. 3, A and  B) . In contrast, in chronic leptin-treated rats insulin failed to promote the IR autophosphorylation and the tyrosine phosphorylation of IRS-1 (Fig. 3, A and B) but further increased the content of IRS-1 phosphorylation on the inhibitory Ser307 (Fig. 3C) .
Central leptin alters Akt phosphorylation in WAT in response to in vivo insulin stimulation
Next we examined the effect of leptin treatment on Akt phosphorylation in WAT upon in vivo insulin stimulation. In pair-fed rats, as expected, insulin administration stimulated Akt Ser473 and Thr308 phosphorylation at the PM, and this activated state of the enzyme was maintained at the cytoplasm fraction (Fig. 4, A-D) . In contrast, leptin treatment increased the basal Akt Ser473 phosphorylation in both compartments (Fig. 4 , A and C) without affecting basal Akt Thr308 phosphorylation (Fig. 4B) . Surprisingly, upon insulin stimulation of leptin-treated rats, phosphorylation of Ser473 decreased near to the basal levels of control rats at the PM (Fig. 4A) . Our data also indicate that the Akt distributed throughout the cytoplasm is unresponsive to insulin in leptin-treated rats (Fig. 4, C and D) .
Effects of central leptin on IR, IRS-1, and GLUT4 mRNA and total protein levels in rat WAT
To further investigate the molecular mechanisms involved in central leptin action on insulin signaling in WAT, we examined the effects of a 7-d central leptin infusion on the mRNA and total protein levels of IR isoforms, IRS-1, and GLUT4 in rat eWAT.
The IR occurs in WAT as two alternatively spliced isoforms, IR-A (exon 11Ϫ) and IR-B (exon 11ϩ) (34) . To quantify the differential expression of IR-A and IR-B, specific primers were used in each case. Central leptin admin- istration did not affect either the gene expression of the IR isoforms (Fig. 5D ) or total IR protein levels (Fig. 5A ) in WAT. However, both IRS-1 (Fig. 5, B and D) and GLUT4 (Fig. 5 , C and D) mRNA and total protein levels significantly decreased in leptin-infused compared with pair-fed rats.
Chronic central leptin treatment increases SOCS3 and resistin mRNA and protein levels in rat WAT: effect of autonomic denervation
Having determined the effects of central leptin on early steps of insulin signaling pathway involved in glucose uptake in WAT, and because SOCS3 and resistin are two potentially negative regulators of insulin signaling, we decided to examine the expression levels of both proteins in rWAT upon central leptin administration. Our results show that SOCS3 mRNA (Fig. 6C ) and protein levels (Fig.  6A) were increased in leptin-infused compared with pair-fed control rats. Moreover, a marked increase of 4.7-fold in mRNA (Fig. 6C ) and 3.6-fold in resistin protein levels (Fig. 6B) was also observed in leptin-infused rats compared with the pair-fed ones. Central leptin treatment also induced similar changes in eWAT (Supplemental Fig. 1 published on The Endocrine Society's Journals Online web site at http:// endo.endojournals.org/).
We have demonstrated that surgical autonomic denervation restored the insulin-stimulated glucose uptake in WAT in central leptin treated rats (Fig.  1B) . Thus, we next assessed whether denervation of the rWAT would also attenuate the up-regulation of SOCS3 and resistin expression after central leptin administration. Surgical autonomic denervation resulted in a modest but statistically significant decrease in the mRNA and, to a higher extent, in the protein levels of both SOCS3 and resistin (Fig. 6) . In fact, upon denervation SOCS3 protein levels were similar to pair-fed control rats, whereas there was a ϳ1.7-fold decrease in resistin protein levels. Collectively, these data support that these proteins could contribute to the inhibitory effect of central leptin on glucose uptake in WAT.
Effect of resistin on glucose uptake in WAT explants
Although central leptin administration for 7 d increases resistin mRNA and protein levels in WAT (Fig. 6 and Supplemental Fig. 1) , interestingly, central leptin infusion did not alter plasma resistin levels (Table 1) . These data suggest that resistin, acting nearby the WAT, is likely to cause local but not systemic insulin resistance. To directly address the effects of resistin on glucose uptake in this tissue, we preincubated rWAT explants with resistin (200 ng/ml) for 4 h and then analyzed the glucose uptake in the absence or presence of insulin. As shown in Fig. 7 , no significant differences were found in basal glucose uptake values (14.39 Ϯ 1.5 vs. 16.35 Ϯ 1.8 pmol 2-deoxyglucose/mg tissue, n ϭ 4; P not significant) in WAT explants preincubated with or without resistin, respectively. However, there was a 37% significant decrease in the insulin-stimulated glucose transport in WAT explants preincubated with resistin compared with untreated controls (17.05 Ϯ 2.5 vs. 26.87 Ϯ 3.1 pmol 2-deoxyglucose/mg tissue, respectively; n ϭ 4; P Ͻ 0.01). Although insulin did increase glucose uptake above control in the presence of resistin the magnitude of the response was significantly attenuated (1.18-fold vs. 1.64-fold; P Ͻ 0.01) in the presence or in the absence of resistin, respectively, after insulin stimulation.
Discussion
Several studies have reported that central or peripheral leptin treatment enhances whole-body insulin sensitivity in terms of glucose metabolism but promotes insulin-resistance in WAT (2-4). While the peripheral actions of leptin are known to take place through leptin receptors, the neural pathways and the neurochemical phenotypes of the neurons constituting the autonomic nervous circuits which transmit leptin signal to WAT are largely unknown (35) . Nevertheless, it is well established that central leptin, independently of its effects on food intake, regulates WAT lipid metabolism by increasing lipolysis and suppressing de novo lipogenesis (27, 29, 36) . However, the mechanisms underlying the inhibitory effect of central leptin on the insulin-dependent glucose uptake in WAT, which may contribute to decrease glucose availability for free fatty acid (FFA) esterification and lipid deposition in this tissue, are not completely understood.
In the present study we provide new insights on the mechanisms by which central leptin regulates glucose uptake in WAT: inhibition of insulin-stimulated tyrosine Densitometric results are the mean Ϯ SEM of three to four rats per group (*, P Ͻ 0.05; **, P Ͻ 0.005; ***, P Ͻ 0.001). SS, vehicle-infused ad libitum-fed rats; PF, vehicle-infused per-fed rats; Lep, leptin-infused rats.
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phosphorylation of IR and IRS-1, suppression of Akt activation, the down-regulation of the mRNA and protein levels of both IRS-1 and GLUT4, and suppression of insulin-stimulated GLUT4 insertion at the PM. As a result, the glucose uptake in WAT was impaired in central leptintreated rats, an effect that was dependent of an intact autonomic nervous system. In fact, surgical denervation of WAT abolished the inhibitory effect of leptin on glucose uptake and restored the insulin stimulation of glucose transport in this tissue. Our results agree with previous data showing that the inhibition of WAT lipogenesis in rats by central leptin is lost after surgical WAT denervation (27) . The fact that plasma leptin does not increase after chronic central leptin administration excludes that the observed effects of this treatment were attributable to peripheral actions of the hormone. A major finding of the present work is that the effects of central leptin on insulin signaling in WAT were paralleled with the marked up-regulation of SOCS3 and resistin mRNA and protein levels in WAT upon central leptin administration. Because plasma resistin levels were not modified upon central leptin treatment but were significantly increased in WAT, these data suggest that central leptin, increasing resistin and SOCS3 levels in WAT, could contribute to tissue-specific but not systemic insulin resistance. Supporting this contention, it has been reported that resistin, inducing SOCS3 expression, attenuates early steps of insulin signaling pathway (IR autophosphorylation, IRS-1 tyrosine phosphorylation, and Akt activation) in 3T3-L1 adipocytes, while the inhibition of SOCS3 function, expressing a dominant negative SOCS protein, prevented resistin from antagonizing insulin action in adipocytes (22) .
The inhibitory effect of central leptin on insulin-stimulated glucose uptake in WAT could be mediated by the melanocortin receptor (MCR) system. In fact, the intracerebroventricular infusion of SHU9119, a MCR antagonist, significantly decreased the glucose uptake in brown adipose tissue, heart, and skeletal muscle while increasing glucose uptake as well as TAG synthesis and deposition in WAT in rats, under clamp conditions (37) . On the other hand, the intracerebroventricular injection of SHU9119 abolished the stimulatory effect on glucose uptake in peripheral tissues induced by leptin injection into the ventromedial hypothalamus except in WAT (38) . These results suggest that MCR system is necessary for the control of glucose uptake by peripheral tissues induced by central leptin.
We have previously shown that in hyperleptinemic aged insulin resistant rats a reduction in the expression of the IR-B isoform occurs, without changes in IR-A (34). Thus, we hypothesized that chronic central leptin could affect the mRNA levels of the IR isoforms. Central leptin administration for 7 d did not affect the IR isoform gene expression or total IR protein levels but inhibited the in vivo insulin stimulation of IR autophosphorylation. Our data also indicate that chronic central leptin inhibited the insulin-stimulated IRS-1 tyrosine phosphorylation, increased IRS-1 phosphorylation on Ser307, which is well known to promote IRS-1 degradation (39) , and this was accompanied by reduced IRS-1 mRNA and protein levels. These changes occurred in parallel with the marked upregulation of SOCS3 upon central leptin administration reported herein. SOCS3 is known to act as a negative regulator of insulin signaling, inhibiting the insulin-stimulated tyrosine phosphorylation of IR and IRS-1 (19, 20, 40) , and promoting IRS-1 protein degradation (39, 41) . Although we have not directly addressed IRS-1 protein degradation, our results suggest that central leptin could drive IRS-1 to proteasome degradation. In fact, central leptin promotes a ϳ2.2-fold higher decrease in IRS-1 total protein than in mRNA levels. Taken together, our results demonstrate that central leptin inhibits early steps of the signaling pathway normally used by insulin in the regulation of glucose uptake in WAT. Full activation of Akt by insulin requires hierarchical phosphorylation of two residues, Thr308 and Ser473, by the PDK1 protein kinase and the Rictor-mammalian target of rapamycin complex (mTORC)2, respectively (42, 43) . Thus, we next examined the effect of central leptin on in vivo insulin stimulation of Akt phosphorylation and GLUT4 translocation to the PM. It has previously been reported that Akt Ser473-phosphorylation in liver and muscle in rodents was unaltered (13) or increased upon peripheral leptin treatment in vivo (44, 45) . The results presented herein demonstrate that central leptin elicits an increase in the basal content of Akt Ser473-phosphorylation and inhibits normal Akt activation after insulin stimulation. Consequently, central leptin impairs the in vivo insulin-stimulated GLUT4 insertion at the PM in WAT. Moreover, leptin decreases GLUT4 mRNA and protein levels, which agrees with previous data in sc leptintreated rats (4) . As a result, the insulinstimulated glucose uptake in WAT was impaired in central leptin-treated rats. As the main role of insulin in WAT is to promote the incorporation of glucose into TAG, the inhibition of glucose uptake by central leptin may contribute to regulate glucose availability for FFA esterification and to control lipid deposition in this tissue. In addition, there is evidence reporting that central leptin administration decreased both lipoprotein lipase expression and FFA uptake in WAT (27) . All these observations, together with the decrease in the visceral fat weight and in the content of TAG in WAT in leptin-treated rats reported herein, are consistent with the putative function of the hormone in regulating adiposity.
In addition to the role of Akt on insulin-stimulated glucose uptake, it has been shown that the pharmacological inhibition of Akt resulted in a reduction in basal and insulin-stimulated lipogenesis in isolated rat adipocytes (46) . Thus, the suppression of insulin-stimulated Akt activation in leptin-treated rats reported herein could be consistent with previous data showing the inhibition of WAT lipogenesis by central leptin (27) . Moreover, insulin signaling via PI3K/Akt activates mTORC1 leading to increased hepatic lipogenesis (47) . In addition, the activation of mTORC1 signaling in 3T3-L1 adipocytes by ectopic expression of Rheb increases de novo lipogenesis and promotes intracellular accumulation of TAG, while the inhibition of mTORC1 signaling by rapamycin or by knock down of raptor stimulates lipolysis primarily via activation of ATGL expression (48) . Consequently, it can be speculated that the inhibition by central leptin of insulin-stimulated Akt activation reported herein could affect mTORC1 activation and ATGL expression in WAT. In support of this, we have previously shown that central leptin administration significantly increased ATGL expression in WAT (29) and impaired the insulinmediated phosphorylation of both mTOR and S6K in this tissue (unpublished data). These results are consistent with the inhibition by leptin of the insulin-stimulated Akt activation reported herein. Nevertheless, these suggestions need further work before a final conclusion may be drawn.
Several hormones and cytokines associated with insulin resistance, such as leptin, insulin, IL-6, TNF-␣, and resistin, induce SOCS3 expression acting directly on adipocytes in vitro (12, 20 -22) . Because SOCS3 expression in WAT in mice is induced after an ip resistin injection (22), we hypothesized that resistin expression in WAT could be up-regulated by central leptin. Contrary to previous data showing either no change or decreased resistin mRNA levels in WAT upon central leptin infusion (49, 50) , we found that central leptin, infused at a 50-fold lower concentration than in previous studies (49, 50) , markedly increased resistin mRNA and total protein levels in WAT, without affecting plasma resistin levels. Although we cannot establish a direct association between central leptin effects on insulin signaling and resistin up-regulation in WAT, several lines of evidences suggest that resistin, acting in an autocrine/paracrine manner, might lead to WAT insulin resistance. First, local autonomic denervation of WAT restored the insulin stimulation of glucose uptake, and this was paralleled by the marked decrease in SOCS3 and resistin protein levels in this tissue. Although the resistin protein content was still higher in leptin-treated than in pair-fed control rats upon denervation, it can be argued that resistin, at the protein levels reported herein, might not be sufficient to inhibit the glucose transport in response to insulin. In fact, it has been reported that the complete inhibition of insulin-stimulated glucose uptake was observed between 100 to 500 nM resistin in L6 skeletal muscle cells (51) . Because the immunoblot analyses provide relative protein data, additional studies have to be done before a final conclusion may be drawn. Second, in agreement with previous data analyzing the direct effect of resistin on glucose uptake in 3T3-L1 adipocytes (52) and L6 cells (53) or in 3T3-L1 adipocytes stably expressing resistin (54), we demonstrate that resistin decreased insulin stimulation of glucose uptake in WAT explants. This observation provides direct support for the evidence that, upon central leptin administration, the up-regulation of resistin levels in WAT can contribute to the inhibition of the insulin-stimulated glucose uptake in this tissue. Finally, our data are consistent with previous reports showing that resistin inhibits the early steps of insulin signaling pathway involved in glucose uptake in 3T3-L1 adipocytes (52, 54) and L6 cells (53) . Nevertheless, the contribution of other factors promoting insulin resistance in WAT upon central leptin administration should be taken into account. In fact, central leptin increases both SOCS3 and IL-6 mRNA levels in WAT (27) . Thus, we suggest that the adipose-derived factor resistin and the cytokine suppressor SOCS3 could be implicated in the local attenuation of the insulin action in WAT upon chronic central leptin treatment.
In conclusion, we have shown that leptin, acting at a central level, negatively modulates early steps of the signaling pathway normally used by insulin in the regulation of glucose uptake in WAT. Because local autonomic denervation of WAT abolished the inhibitory effect of central leptin on glucose transport and decreased SOCS3 and resistin levels in this tissue, our data also suggest that resistin might be a mediator of central leptin antagonism of insulin action in WAT. Because glucose uptake from extracellular sources is an important step to promote TAG formation and de novo lipogenesis in WAT, the inhibition of glucose uptake by central leptin may contribute to regulate excessive fat mass enlargement, a factor known for playing a key role in the development of overall insulin resistance.
